Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs

Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to $640 million in milestones, plus royalties.